Peptides Sexual Wellness
PT-141 (Bremelanotide)
Bremelanotide · Vyleesi
Melanocortin agonist approved for acquired, generalized hypoactive sexual desire disorder in women.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.1 days
- Bioavailability
- 50%
- Typical dose
- 0.5–2 mg